Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)
- 5 June 2017
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Investigational Drugs
- Vol. 26 (7), 803-811
- https://doi.org/10.1080/13543784.2017.1335711
Abstract
Introduction: Acute myelogenous leukemia (AML) is a heterogeneous group of malignancies driven by genetic mutations and deregulated epigenetic control. Relapse/refractory disease remains frequent in younger patients and even more so in older patients, including treatment with epigenetic drugs in this age group, mainly with hypomethylating agents. New treatment strategies are urgently needed. The recent discovery that epigenetic readers of the bromodomain (BRD) and extraterminal (BET) protein family, are crucial for AML maintenance by transcription of oncogenic c-MYC lead to rapid development of BET inhibitors entering clinical trials. Areas covered: We provide a critical overview using main sources for the use of BET inhibitors in AML treatment. Limits of this treatment approach including resistance mechanisms and future directions including development of new generation BET inhibitors and combination strategies with other drugs are detailed. Expert opinion: BET inhibitors were expected to overcome limits of conventional treatment in patients as impressive in vitro data emerged recently in well-characterized AML subsets, including those associated with poor risk characteristics in the clinic. Nevertheless single activity of BET inhibitors appears to be modest and resistance mechanisms were already identified. BET inhibitors with alternative mechanisms of action and/or combination strategies with epigenetic drugs should be tested.Keywords
This publication has 70 references indexed in Scilit:
- MRD in AML: does it already guide therapy decision-making?Hematology, 2016
- An update of current treatments for adult acute myeloid leukemiaBlood, 2016
- Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemiaBlood, 2016
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsBlood, 2015
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2012
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongationBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2011
- Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemiaLeukemia, 2010
- Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcriptionProceedings of the National Academy of Sciences of the United States of America, 2007
- The Core Histone N-Terminal Tail Domains Negatively Regulate Binding of Transcription Factor IIIA to a Nucleosome Containing a 5S RNA Gene via a Novel MechanismMolecular and Cellular Biology, 2005